A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Onartuzumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Roche
- 05 Dec 2016 Primary endpoint (Progression-free survival (investigator-assessed): onartuzumab + bevacizumab versus placebo + bevacizumab) has not been met according to the results published in the Journal of Clinical Oncology.
- 05 Dec 2016 Results published in the Journal of Clinical Oncology.
- 24 Oct 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database record.